Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.02 | 0.0269 | 0.0269 |
Giardia lamblia | Macrophage migration inhibitory factor | 0.3236 | 1 | 0.5 |
Trypanosoma brucei | C-8 sterol isomerase, putative | 0.0391 | 0.0881 | 0.5 |
Trichomonas vaginalis | macrophage migration inhibitory factor, mif, putative | 0.3236 | 1 | 0.5 |
Entamoeba histolytica | macrophage migration inhibitory factor-like protein | 0.3236 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0391 | 0.0881 | 0.0881 |
Trichomonas vaginalis | conserved hypothetical protein | 0.3236 | 1 | 0.5 |
Loa Loa (eye worm) | macrophage migration inhibitory factor | 0.3236 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.012 | 0.0014 | 0.0014 |
Trypanosoma cruzi | C-8 sterol isomerase, putative | 0.0391 | 0.0881 | 0.5 |
Plasmodium falciparum | macrophage migration inhibitory factor | 0.3236 | 1 | 0.5 |
Schistosoma mansoni | integrin alpha | 0.0153 | 0.0119 | 0.5 |
Loa Loa (eye worm) | integrin alpha pat-2 | 0.0236 | 0.0385 | 0.0385 |
Plasmodium vivax | macrophage migration inhibitory factor, putative | 0.3236 | 1 | 0.5 |
Loa Loa (eye worm) | macrophage migration inhibitory factor 2 | 0.1381 | 0.4053 | 0.4053 |
Brugia malayi | Integrin alpha pat-2 precursor | 0.0153 | 0.0119 | 0.0119 |
Leishmania major | macrophage migration inhibitory factor-like protein | 0.3236 | 1 | 1 |
Loa Loa (eye worm) | macrophage migration inhibitory factor 2 | 0.1381 | 0.4053 | 0.4053 |
Echinococcus granulosus | integrin alpha 3 | 0.0117 | 0.0005 | 0.5 |
Toxoplasma gondii | macrophage migration inhibitory factor, putative | 0.3236 | 1 | 0.5 |
Echinococcus multilocularis | integrin alpha 3 | 0.0117 | 0.0005 | 0.5 |
Leishmania major | macrophage migration inhibitory factor-like protein | 0.3236 | 1 | 1 |
Brugia malayi | ERG2 and Sigma1 receptor like protein | 0.0391 | 0.0881 | 0.0881 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (ADMET) | > 100 ug ml-1 | Cytotoxicity against human HT29 cells after 72 hrs by MTT assay | ChEMBL. | 17373779 |
IC50 (ADMET) | > 100 ug ml-1 | Cytotoxicity against human DU145 cells after 72 hrs by MTT assay | ChEMBL. | 17373779 |
IC50 (ADMET) | > 100 ug ml-1 | Cytotoxicity against human KB cells after 72 hrs by MTT assay | ChEMBL. | 17373779 |
IC50 (ADMET) | > 100 ug ml-1 | Cytotoxicity against human L132 cells after 72 hrs by MTT assay | ChEMBL. | 17373779 |
IC50 (ADMET) | > 100 ug ml-1 | Cytotoxicity against human MiaPaCa2 cells after 72 hrs by MTT assay | ChEMBL. | 17373779 |
IC50 (ADMET) | > 100 ug ml-1 | Cytotoxicity against human Hep2 cells after 72 hrs by MTT assay | ChEMBL. | 17373779 |
IC50 (ADMET) | > 100 ug ml-1 | Cytotoxicity against human PA1 cells after 72 hrs by MTT assay | ChEMBL. | 17373779 |
IC50 (ADMET) | > 100 ug ml-1 | Cytotoxicity against human ECV304 cells after 72 hrs by MTT assay | ChEMBL. | 17373779 |
IC50 (ADMET) | > 100 ug ml-1 | Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay | ChEMBL. | 17373779 |
IC50 (ADMET) | > 100 ug ml-1 | Cytotoxicity against human HT29 cells after 72 hrs by MTT assay | ChEMBL. | 17373779 |
IC50 (ADMET) | > 100 ug ml-1 | Cytotoxicity against human DU145 cells after 72 hrs by MTT assay | ChEMBL. | 17373779 |
IC50 (ADMET) | > 100 ug ml-1 | Cytotoxicity against human KB cells after 72 hrs by MTT assay | ChEMBL. | 17373779 |
IC50 (ADMET) | > 100 ug ml-1 | Cytotoxicity against human L132 cells after 72 hrs by MTT assay | ChEMBL. | 17373779 |
IC50 (ADMET) | > 100 ug ml-1 | Cytotoxicity against human MiaPaCa2 cells after 72 hrs by MTT assay | ChEMBL. | 17373779 |
IC50 (ADMET) | > 100 ug ml-1 | Cytotoxicity against human HEK293 cells after 72 hrs by MTT assay | ChEMBL. | 17373779 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.